| Literature DB >> 19833080 |
Sylvia Janetzki, Cedrik M Britten, Michael Kalos, Hyam I Levitsky, Holden T Maecker, Cornelius J M Melief, Lloyd J Old, Pedro Romero, Axel Hoos, Mark M Davis.
Abstract
Immunotherapy, especially therapeutic vaccination, has a great deal of potential in the treatment of cancer and certain infectious diseases such as HIV (Allison et al., 2006; Fauci et al., 2008; Feldmann and Steinman, 2005). Numerous vaccine candidates have been tested in patients with a variety of tumor types and chronic viral diseases. Often, the best way to assess the clinical potential of these vaccines is to monitor the induced T cell response, and yet there are currently no standards for reporting these results. This letter is an effort to address this problem.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19833080 PMCID: PMC3762500 DOI: 10.1016/j.immuni.2009.09.007
Source DB: PubMed Journal: Immunity ISSN: 1074-7613 Impact factor: 31.745